Leadership Team
Management Team
Under the leadership of Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes more than 20 accomplished leaders with expertise in business, biopharmaceutical research, genetic medicine, finance, clinical, government and regulatory affairs, manufacturing, pharmacological sciences, sales, marketing and human resources. Supported by a staff of approximately 600 employees worldwide, BioMarin is focused on delivering first-to-market therapies to patients with rare genetic diseases.
| Jean-Jacques Bienaimé Chief Executive Officer |
Steven Jungles Vice President, Supply Chain |
| Jeffrey H. Cooper Senior Vice President, Chief Financial Officer |
Daniel P. Maher Senior Vice President of Product Development |
| Henry J. Fuchs, M.D. Executive Vice President and Chief Medical Officer |
Charles A. O'Neill, Ph.D. Vice President, Pharmacological Sciences |
| Jeff Ajer Vice President Commercial Operations, The Americas |
Dan Oppenheimer, Ph.D. Vice President, Portfolio Strategy |
| Stephen Aselage Executive Vice President and Chief Business Officer |
R. Andrew Ramelmeier Vice President, Manufacturing and Process Development |
| Robert A. Baffi, Ph.D. Executive Vice President Technical Operations |
Ed Von Pervieux Vice President and Chief Information Officer |
| Luisa Bigornia Vice President, Intellectual Property |
Victoria Sluzky, Ph.D. Vice President, Quality and Analytical Chemistry |
| Lewis Chapman Vice President, Global Marketing |
Gordon Vehar, Ph. D. Vice President, Research |
| G. Eric Davis Senior Vice President and General Counsel |
Amy Waterhouse Vice President, Regulatory and Government Affairs |
| Joshua A. Grass Vice President, Corporate and Business Development |
Mark Wood Vice President, Human Resources |
| Brian Mueller Vice President, Controller |
Jackie Walling, M.D., Ph.D. Vice President, Clinical Development |
Board of Directors
| Jean-Jacques Bienaimé Chief Executive Officer |
Pierre Lapalme 4 Former President and Chief Executive Officer, North America Ethypharm, Inc. |
| Michael Grey 5 Former President and Chief Executive Officer of Auspex Pharmaceuticals, Inc. |
V. Bryan Lawlis 5,6 President and Chief Executive Officer, Itero Biopharmaceuticals, Inc. |
| Elaine Heron 3,4 Chairman and Chief Executive Officer, Amplyx Pharmaceuticals, Inc. |
Alan Lewis 2 President and Chief Executive Officer, Juvenile Diabetes Research Foundation |
| Joseph Klein, III 1,6 Managing Director, Gauss Capital Advisors, LLC. |
Randy Meier 3,4 |
| 1 Chairman, Audit Committee 2 Chairman, Compensation Committee 3 Chairman, Governance Committee 4 Member, Audit Committee 5 Member, Compensation Committee 6 Member, Governance Committee |
Science Advisory Board
| Jeffrey Borer, M.D. Director, The Howard Gilman Institute for Valvular Heart Diseases Weill Medical College of Cornell University New York, New York |
Joseph Loscalzo, M.D., Ph.D. Chairman, Department of Medicine Brigham and Women's Hospital Boston, Massachusetts Editor in Chief, Circulation |
| Raymond C. Stevens, Ph.D. Professor of Molecular Biology & Chemistry The Scripps Research Institute La Jolla, California |
David L. Rimoin, M.D., Ph.D. Steven Spielberg Chair and Director, Medical Genetics Institute Director, International Skeletal Dysplasia Registry Cedar-Sinai Medical Center Los Angeles, California |
| Robert Langer, Sc.D. Professor of Toxicology and BEH Massachusetts Institute of Technology Cambridge, Massachusetts |
Larry J. Shapiro, M.D. Spencer T. and Ann W. Olin Distinguished Professor Executive Vice Chancellor for Medical Affairs and Dean Washington University School of Medicine St. Louis, Missouri |
| Alan J. Lewis, Ph.D. President and CEO Juvenile Diabetes Research Foundation New York, New York |
John Urquhart, M.D. Chief Scientist AARDEX Ltd. |
